HOME >> BIOLOGY >> NEWS
DOE Joint Human Genome Effort Exceeds Sequencing Goal

Facility (PSF), in November. The PSF will provide 56,600 square feet of laboratory and office space, accommodating at its capacity 200 researchers working in three shifts around the clock. The genomic technologies being developed by the JGI and other efforts around the world, he said, will provide the basic information about human genes needed to address many issues related to disease diagnosis and therapy.

Defective genes directly account for more than 4,000 hereditary human diseases -- including such maladies as Huntington disease and cystic fibrosis. In some such cases, a single misplaced letter among the three-billion-letter code can lead to a disease state.

The benefits of the genome project are already coming to light. A new era of molecular medicine is envisioned that is characterized not by treating symptoms, but rather by looking to the deepest causes of disease. Rapid and more accurate diagnostic tests will make possible earlier treatments. Insights into genetic susceptibilities to disease and to environmental damage, coupled with highly targeted pharmaceuticals, may soon help to attack diseases at their molecular foundations.

The DOE, with a long-abiding mission to understand and characterize the potential health risks posed by energy use and production, has established an unparalleled scientific and engineering infrastructure in its national laboratories and a track record of success in conducting large-scale multidisciplinary projects. In 1986, the DOE was the first federal agency to launch a major initiative to completely decipher the entire human genetic code. Building on the JGI's accomplishment this year, the DOE, according to Krebs, will invest approximately $250 million in the Joint Genome Institute over the next five years.

The full text of the genome program's five-year plan can be found at http://www.ornl.gov/hg5yp on the World Wide Web.


'"/>

Contact: David Gilbert
degilbert@lbl.gov
510-486-6096
DOE/Lawrence Berkeley National Laboratory
23-Oct-1998


Page: 1 2 3

Related biology news :

1. 7th Joint Conference on Information Sciences
2. UC Berkeley, Joint Genome Institute target chloroplasts for clues to green plant evolution
3. Joint Genome Institute to sequence key African frog genome
4. Joint research project to improve butterfly identification system
5. Sequencing Milestone Reached By DOE Joint Genome Institute
6. University Of Kentucky Biomedical Engineer Awarded Grant To Improve Joint Replacements And Dental Implants
7. NIST Machine To Aid In Making Better Artificial Joints
8. First Evidence That Localized Arthritis Gene Therapy Heals Distant Diseased Joints
9. Human chromosome 5 final sequence analysis released to public
10. Humans march to a faster genetic drummer than primates, UC Riverside research says
11. Applied Mathematical Models in Human Physiology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: DOE Joint Human Genome Effort Exceeds Sequencing Goal

(Date:6/17/2013)... by fungi, bacteria, and algae, is a common component ... used in the medical field it,s approved by ... fluids and used during surgery as a substance that ... other drugs. , Now Profs. Ehud Gazit and Daniel ... and Biotechnology and the Sagol School of Neuroscience, along ...
(Date:6/17/2013)... will be the topics under discussion during the ... the third consecutive year, this will be a ... experiences among members of Academy, Business, Educators, Entrepreneurs, ... speakers: Elisa Martn Garijo (IBM South Europe), Chris ... Mary O,Donovan (Hovione), among others. E3 Forum - ...
(Date:6/17/2013)... available in French . ... older mice with Alzheimer,s disease can be reversed with treatment. ... Hospital - The Neuro, at McGill University and at Universit ... receptor in the brain of mice with advanced Alzheimer,s disease ... the Journal of Neuroinflammation in May, also suggest ...
Breaking Biology News(10 mins):Artificial sweetener a potential treatment for Parkinson's disease 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2Blocking overactive receptor in Alzheimer's recovers memory loss and more 2
(Date:6/14/2013)... 2013  Royalty Pharma notes today,s announcement by Elan Corporation, ... explore a sale of the Company. Royalty Pharma believes it ... certainty that a deal will ever be reached. Royalty Pharma calls ... AGAINST all four resolutions up for consideration at Elan,s EGM ... formal offer for Elan. In response to the announcement ...
(Date:6/14/2013)... June 14, 2013 The OpenClinica ... Hotel, Boston, MA this year with Formedix CEO, Mark ... valuable sessions, offering attendees a deeper insight into the ... with partners, such as Formedix to develop innovative solutions. ... to learn all about OpenClinica, hear real-life case studies ...
(Date:6/14/2013)... June 14, 2013 The Pittcon Exposition ... 2014, which will be held March 3-6, 2014, at ... Chicago, Illinois. The cost per booth after July 15, ... the first round of booth assignments should have their ... placements will begin August 2013. , Pittcon attracts a ...
(Date:6/14/2013)...  The Pittsburgh Life Sciences Greenhouse (PLSG) today announced ... were necessitated by delays in portfolio company exits caused ... of state funding. PLSG President and CEO, ... only pure life sciences investment firm, the actions taken ... of Directors, were necessary to protect the future of ...
Breaking Biology Technology:Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 2Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 3Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 4Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 5Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 6Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 7Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 8Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 9Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 10Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty 11Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 2Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston 3Pittcon 2014 Now Accepting Booth Space Reservations 2Pittsburgh Life Sciences Greenhouse Makes Significant Reductions Due to Uncertain Funding 2
Cached News: